Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats.
about
Sustained glucagon-like peptide-2 infusion is required for intestinal adaptation, and cessation reverses increased cellularity in rats with intestinal failure.Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndromeEmerging treatment options for short bowel syndrome: potential role of teduglutideMechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblastsTherapeutic effects of different doses of polyethylene glycosylated porcine glucagon-like peptide-2 on ulcerative colitis in male ratsEnteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure.Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion.Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats.Generation of glucagon-like peptide-2-expressing Saccharomyces cerevisiae and its improvement of the intestinal health of weaned rats.Whey protein potentiates the intestinotrophic action of glucagon-like peptide-2 in parenterally fed ratsReview article: a comparison of glucagon-like peptides 1 and 2.Teduglutide for Safe Reduction of Parenteral Nutrient and/or Fluid Requirements in Adults: A Systematic Review.Colonic GLP-2 is not sufficient to promote jejunal adaptation in a PN-dependent rat model of human short bowel syndrome.The prolonged effect of glucagon-like peptide 2 pretreatment on growth performance and intestinal development of weaned piglets.The role of angiotensin II type 1a receptor on intestinal epithelial cells following small bowel resection in a mouse modelStimulation of intestinal growth and function with DPP4 inhibition in a mouse short bowel syndrome model.
P2860
Q34425937-5EAFF31F-7C45-4FD6-B5C0-A2B4F9D8EE37Q35141322-69662706-EBE4-40F5-9969-9C5ADF24A250Q35304614-2B9F3317-AD7F-4082-B59A-CD7CCA3F8CE6Q36063090-C94E9F34-155D-4007-BC5C-C9B76F666821Q36297218-A0A87AF6-55CD-42E1-A54C-0AFB7E20E5C7Q36309586-EA0F1B36-E43C-48C8-888A-2354783D3598Q37138788-98977BE9-BCAB-4416-A3E5-BA3A816B02FEQ37200132-38D3AF8B-59AD-417B-8AF8-733016A06C32Q37353504-1C947FB2-6689-4F21-B893-AB3A86279FA8Q37422061-1CD83E92-64ED-49FE-AF9A-A8CD537D3796Q38057350-65F15502-D95B-4E29-B370-76DD4D4E8348Q38425331-CFF7FACC-CFAC-4CFB-A8D2-FD2187C90B54Q39974467-90C8E91C-AE1A-4D85-B4DB-54731EDE5ED1Q40961749-C3F20216-765A-4082-A241-4B4F58B5BC60Q42231792-0AE6852C-145D-4921-A2F6-5B41E7A97AC2Q55073464-1BD69D45-9FFB-45CF-AAF1-55907576BB33
P2860
Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Exogenous glucagon-like peptid ...... mRNA levels in resected rats.
@en
Exogenous glucagon-like peptide-2
@nl
type
label
Exogenous glucagon-like peptid ...... mRNA levels in resected rats.
@en
Exogenous glucagon-like peptide-2
@nl
prefLabel
Exogenous glucagon-like peptid ...... mRNA levels in resected rats.
@en
Exogenous glucagon-like peptide-2
@nl
P2093
P2860
P356
P1476
Exogenous glucagon-like peptid ...... mRNA levels in resected rats.
@en
P2093
David W Nelson
Denise M Ney
Mark S Brownfield
Matthew C Koopmann
Sangita G Murali
Xiaowen Liu
P2860
P304
P356
10.1177/0148607108316198
P577
2008-05-01T00:00:00Z